Fig. 1 · Structure

Documents & Downloads

Cefazolin Sodium

Cat. No. A16434 CAS 27164-46-1
Cefazolin Sodium is a semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. It attains high serum levels and is excreted quickly via the urine.

In Stock

Publications for Cefazolin Sodium

1 publication citing this product

  1. Viktoria Lazar, .et al. , Nature, 2022, 610: 540-546 PMID: 36198788

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

In Staphylococcus aureus lysate, cefazolin sodium at 10 µM stabilized PBP3 relative to vehicle, supporting PBP target engagement. This protein-solubility assay does not establish catalytic inhibition or an antibacterial IC50. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
β-lactam  

Cefazolin Sodium Research Summary

This section summarizes 1 in vitro study and 1 in vivo study of Cefazolin Sodium from 2 published references.

Cefazolin Sodium In Vitro Studies

Cefazolin sodium target engagement in bacterial lysate

Biochemical assay · Staphylococcus aureus Newman cell lysate; solvent-induced protein precipitation with quantitative mass spectrometry [1]

At 10 µM, cefazolin sodium increased soluble PBP3 abundance versus vehicle (n = 3 per condition), consistent with PBP engagement. Table S3 lists PBP3 among the cefazolin-responsive proteins. This is a lysate stability readout, not a catalytic inhibition, live-cell killing or IC50 assay.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
PBP3 soluble abundance relative to vehicleiSPP stabilization Increased; PBP3 listed as stabilized in Table S3 and shown in Figure S10A[1]

Literature-Reported Treatment Conditions

Treatment concentration
10 µM
Exposure duration
30 min compound incubation before solvent challenge
Method
Cell-lysate iSPP assay
Vehicle
DMSO or ddH2O with corresponding vehicle controls; cefazolin-specific assignment is not explicit in the read main-text methods
Reported limits
No cefazolin dose-response IC50; assay measures protein solubility rather than enzyme inhibition. Exact compound-specific vehicle assignment is unclear.
Methods and source locations

Compound reported in the paper: Cefazolin sodium; Compound label in the paper: Cefazolin

Cefazolin sodium target engagement in lysate only.

Table 1; Results: S. aureus target-engagement paragraphs; iSPP Assay and iSPP Data Analysis; SI Figure S10A (PDF p. 16); Table S3 rows 217–229, especially row 222

PBP3 soluble abundance relative to vehicle: Quantitative DIA mass spectrometry after solvent-induced precipitation; n = 3 drug and n = 3 vehicle. Table S3 uses |log2FC| > 0.3 and p < 0.05 for S. aureus. — SI Figure S10A (PDF p. 16); Table S3 rows 217–222; main model-drug assay results and iSPP Data Analysis

Cefazolin Sodium In Vivo Studies

In lean and obese male rats, a single intravenous mixture containing cefazolin sodium (50 mg/kg), cefoxitin and piperacillin yielded cefazolin plasma half-life estimates of 36 and 37 minutes, respectively. These pooled-profile estimates lack individual-animal variability estimates. The study characterizes disposition during coadministration; drug interactions and translation to humans remain uncertain. [2]

Cefazolin pharmacokinetics in lean and obese rats under three-drug coadministration

Animal study · Male Long-Evans rats, lean and diet-induced obese cohorts, 26 weeks old [2]

After one intravenous three-antibiotic mixture, cefazolin plasma half-life estimates were 36 min in lean and 37 min in obese rats. Plasma AUCinf estimates were 13,654 and 15,895 min·µg/mL, respectively. These are pooled-profile estimates without SD or statistical significance estimates; coadministration prevents attribution to cefazolin alone.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Cefazolin plasma terminal half-lifet1/2 Lean: 36 min; obese: 37 min[2]
Cefazolin plasma exposure extrapolated to infinityAUCinf Lean: 13,654 min·µg/mL; obese: 15,895 min·µg/mL[2]

Conditions shared by the study groups

Route
Intravenous tail-vein bolus
Frequency
Once
Treatment course
Single administration; terminal sampling at 5, 15, 30, 45, 60, 90 and 120 min
Vehicle
Water
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Lean cohort
Cefazolin 50 mg/kg plus cefoxitin 50 mg/kg and piperacillin 120 mg/kg; based on total body weight
Obese cohort given the same mg/kg mixturePlasma t1/2 36 min; AUCinf 13,654 min·µg/mL. Pooled-profile estimates; no SD or significance estimate.[2]
Obese cohort
Cefazolin 50 mg/kg plus cefoxitin 50 mg/kg and piperacillin 120 mg/kg; based on total body weight
Lean cohort given the same mg/kg mixturePlasma t1/2 37 min; AUCinf 15,895 min·µg/mL. Pooled-profile estimates; no SD or significance estimate.[2]
Lean cohort
Model: Male Long-Evans rats, regular-diet lean controls, 26 weeks old; n = 3–5 per time point
Reported limits: No individual longitudinal concentration profiles. No shown monotherapy comparison.
Obese cohort
Model: Male Long-Evans rats, high-fat-diet obese cohort, 26 weeks old; n = 3–5 per time point
Reported limits: No individual longitudinal concentration profiles. No shown monotherapy comparison.
Methods and source locations

Compound reported in the paper: Cefazolin sodium; Compound label in the paper: Cefazolin

Animal disposition under the reported coadministration; no antimicrobial efficacy or human-dose recommendation.

Materials; Animals; Study Design; Pharmacokinetic Analysis and Modeling; Results; Figure 3; Table IV plasma rows and footnote; Discussion, co-dosing limitation

Cefazolin plasma terminal half-life: Noncompartmental analysis of pooled terminal-sampling profiles; n = 3–5 animals per cohort and time point. No SD calculated. — Table IV, Plasma lean/obese rows and footnote; Study Design; Pharmacokinetic Analysis and Modeling

Cefazolin plasma exposure extrapolated to infinity: Noncompartmental analysis of pooled terminal-sampling profiles; no individual profiles or SD available. — Table IV, Plasma lean/obese rows, AUCinf column and footnote

Lean cohort · Animals; Study Design; Table IV Plasma lean row and footnote

Obese cohort · Animals; Study Design; Table IV Plasma obese row and footnote

Specifications

Manufacturer Adooq Bioscience
CAS Number 27164-46-1
Formula C14H14N8O4S3.Na
Molecular Weight 476.49
Synonyms cephazolin sodium; Ancef
SMILES
CC1=NN=C(S1)SCC2=C(N3C(C(C3=O)NC(=O)CN4C=NN=N4)SC2)C(=O)[O-].[Na+]

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 83 mg/mL (174.19 mM)
Water 83 mg/mL (174.19 mM)
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Cefazolin Sodium Research References

  1. [1] Bizzarri L, Steinbrunn D, Quennesson T, et al. Studying Target-Engagement of Anti-Infectives by Solvent-Induced Protein Precipitation and Quantitative Mass Spectrometry ACS infectious diseases (2024). PMID: 39566904 DOI: 10.1021/acsinfecdis.4c00417 Source material
  2. [2] Sheng YH, Kosicka-Noworzyń K, Siemiątkowska A, et al. Physiologically Based Modeling of Cefoxitin, Cefazolin, and Piperacillin Pharmacokinetics in Obese and Lean Rats The AAPS journal (2025). PMID: 40246785 DOI: 10.1208/s12248-025-01063-4 Source material

Publications

1 publication citing this product

  1. Viktoria Lazar, .et al. , Nature, 2022, 610: 540-546 PMID: 36198788

Added to your cart

View Cart Checkout
Loading...